LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

Anika Therapeutics Inc

Open

SectorGezondheidszorg

11.9 -1.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.94

Max

12.09

Belangrijke statistieken

By Trading Economics

Inkomsten

8.1M

-22M

Verkoop

27M

26M

EPS

-0.06

Winstmarge

1,694.961

Werknemers

288

EBITDA

52M

27M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+85.97% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-30M

178M

Vorige openingsprijs

13.47

Vorige sluitingsprijs

11.9

Nieuwssentiment

By Acuity

50%

50%

160 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Anika Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 mei 2025, 17:03 UTC

Winsten
Belangrijke Marktbewegers

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

Peer Vergelijking

Prijswijziging

Anika Therapeutics Inc Prognose

Koersdoel

By TipRanks

85.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.67 USD  85.97%

Hoogste 28 USD

Laagste 19 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Anika Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

14.51 / 14.745Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

160 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.